<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009889</url>
  </required_header>
  <id_info>
    <org_study_id>HSO-PregO-2018</org_study_id>
    <nct_id>NCT04009889</nct_id>
  </id_info>
  <brief_title>Impact of Oral Probiotic Blend on Pregnancy Outcome</brief_title>
  <official_title>Double Blind,Randomized, Controlled Trial on Impact of Oral Probiotic Blend ( Lactobacillus Rhamnosus GG, L. Crispatus LBV88, L. Rhamnosus LBV96, L.Jensenii LBV116 and L. Gasseri LBV150 ) on Pregnancy Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>i-Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>i-Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is, to investigate the effect of oral intake of Lactobacillus rhamnosus&#xD;
      GG (ATCC 53103), Lactobacillus crispatus Lbv88, Lactobacillus rhamnosus Lbv96, Lactobacillus&#xD;
      jensenii Lbv116 Lactobacillus gasseri Lbv150 on outcomes of pregnancy and microbiota and&#xD;
      their interrelation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women aged &gt; 18 years in the &lt; 14th week of pregnancy willing to consume the study&#xD;
      product once daily starting the day after V1 until delivery, complying with inclusion and&#xD;
      exclusion criteria will be enrolled in the study.&#xD;
&#xD;
      After enrollement subjects will be randomly and evenly assigned to one of the two test groups&#xD;
      verum and placebo.&#xD;
&#xD;
      The study population will be recruited in a screening examination ( G1 ) by gynaecologists&#xD;
      from Kiel area.&#xD;
&#xD;
      Primary target parameter of the study :&#xD;
&#xD;
      HOMA-IRa value in week 24-28 (V2), which is based on glucose and insulin measures during the&#xD;
      second oral glucose tolerance test (OGTT)&#xD;
&#xD;
      Secondary target parameters :&#xD;
&#xD;
      HOMA-IR value in week 36-40 , Alteration (V2 - V1) Δ HOMA-IR, Alteration (V2 - V1) Δ QUICKI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Actual">June 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>N=162 pregnant women were randomly assigned to one of the 2 interventions: verum (Lactobacilli) or placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HOMA-IR value in week 24-28</measure>
    <time_frame>measurement between 24-28 week of pregnancy</time_frame>
    <description>HOMA -IR is the product of insulin x glucose and describes the level of insulin resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA-IR value in week 36-40</measure>
    <time_frame>measurement between 36-40 week of pregnancy</time_frame>
    <description>HOMA -IR is the product of insulin x glucose and describes the level of insulin resistance</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Gestational Diabetes Mellitus in Pregnancy</condition>
  <arm_group>
    <arm_group_label>verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>probiotic bland with 5 different lactobacilli</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>capsule containing a probiotic blend of 5 different Lactobacilli</intervention_name>
    <description>n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.</description>
    <arm_group_label>verum</arm_group_label>
    <other_name>verum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.</intervention_name>
    <description>n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant women aged &gt; 18 years in the &lt; 14 week of pregnancy&#xD;
&#xD;
          -  willing to consume the study product during pregnancy ( V1 to delivery)&#xD;
&#xD;
          -  willingness to abstain from probiotic food and supplements containing probiotics&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria: Any of the following is regarded as a criterion for exclusion from&#xD;
        enrollment in the study:&#xD;
&#xD;
          1. Subjects currently enrolled in another clinical study&#xD;
&#xD;
          2. Subjects having finished another clinical study within the last 4 weeks before&#xD;
             inclusion&#xD;
&#xD;
          3. Diabetes mellitus&#xD;
&#xD;
          4. Acute metabolic disorder interfering with glucose metabolism&#xD;
&#xD;
          5. Known cancer &lt; 5y ago&#xD;
&#xD;
          6. Any ano-rectal infection, disease, surgery in the medical history or current which may&#xD;
             have impact on microbiota&#xD;
&#xD;
          7. Anus praeter&#xD;
&#xD;
          8. Hypersensitivity, allergy or idiosyncratic reaction to any component of the test&#xD;
             product&#xD;
&#xD;
          9. Any disease or condition which might significantly compromise the hematopoietic,&#xD;
             renal, endocrine, pulmonary, hepatic, gastrointestinal, cardiovascular, immunological,&#xD;
             central nervous, dermatological or any other body system&#xD;
&#xD;
         10. History of active hepatitis B and C&#xD;
&#xD;
         11. History of HIV infection&#xD;
&#xD;
         12. Regular medical treatment including OTC, which may have impact on the study aims (e.g.&#xD;
             probiotics, antibiotic drugs, laxatives etc.)&#xD;
&#xD;
         13. Major cognitive or psychiatric disorders&#xD;
&#xD;
         14. Present drug abuse or alcoholism, reformed alcoholic Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women aged &gt; 18 years in the &lt; 14 week of pregnancy</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiane Laue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center Kiel GmbH, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>D-24118</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silicon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

